Finoriq research workspace
Amylyx Pharmaceuticals, Inc. (AMLX) SEC Filings & Filing Highlights
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery. Review AMLX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
- Company
- Amylyx Pharmaceuticals, Inc. (AMLX)
- Ticker
- AMLX
- Market Cap
- $2B
- Latest Price
- $17.58
- Industry
- Biotech & Pharma
Amylyx Pharmaceuticals, Inc. (AMLX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Amylyx Pharmaceuticals, Inc. (AMLX).
| Event | Form | Date |
|---|---|---|
| Proposal 1 – Election of Class II DirectorsAmylyx Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 4, 2026 (the “Annual Meeting”). At the Annual... | 8-K5.07 | 2026-06-04 |
| Amylyx Pharmaceuticals Reports First Quarter 2026 Financial ResultsAmylyx Pharmaceuticals Reports First Quarter 2026 Financial Results | 8-K2.02 | 2026-05-07 |
| AVEXITIDE Investigational, First-in-Class GLP-1 Receptor Antagonist with FDA Breakthrough Thera...DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” withi... | 8-K7.01 | 2026-03-24 |
| Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsAmylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | 8-K2.02 | 2026-03-03 |
| AVEXITIDE Investigational, First-in-Class Inhibitor of GLP-1 Receptor Activity with FDA Breakth...DISCLAIMER Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” withi... | 8-K8.01 | 2026-01-08 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.